AI assistant
AbbVie Inc. — Director's Dealing 2023
Jul 10, 2023
29755_dirs_2023-07-10_2e7212c6-0f30-4449-a031-4065ef644fc4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: AbbVie Inc. (ABBV)
CIK: 0001551152
Period of Report: 2023-06-29
Reporting Person: Donoghoe Nicholas (N/A)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock, $0.01 par value | 58815 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Option (Right to buy) | $79.02 | 2029-02-20 | Common Stock (32710) | Direct | |
| Option (Right to buy) | $93.50 | 2030-02-19 | Common Stock (72013) | Direct | |
| Option (Right to buy) | $105.92 | 2031-02-17 | Common Stock (29813) | Direct | |
| Option (Right to buy) | $144.54 | 2032-02-16 | Common Stock (21453) | Direct | |
| Option (Right to buy) | $149.62 | 2033-02-15 | Common Stock (17555) | Direct |
Footnotes
F1: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 10,904 shares on 02/21/2020, as to 10,903 shares on 02/21/2021, and as to 10,903 shares on 02/21/2022.
F2: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 24,005 shares on 02/20/2021, as to 24,004 shares on 02/20/2022, and as to 24,004 shares on 02/20/2023.
F3: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 9,938 shares on 02/18/2022 and as to 9,938 shares on 02/18/2023, and will become exercisable as to as to 9,937 shares on 02/18/2024.
F4: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 7,151 shares on 02/17/2023, and will become exercisable as to 7,151 shares on 02/17/2024 and as to 7,151 shares on 02/17/2025.
F5: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option will become exercisable as to 5,852 shares on 02/16/2024, as to 5,852 shares on 02/16/2025 and as to 5,851 shares on 02/16/2026.